or Try an Advanced Search...

    Technical Analysis for KOD - Kodiak Sciences Inc

    Grade Last Price % Change Price Change
    C 6.19 4.92% 0.29
    KOD closed up 4.92 percent on Friday, November 22, 2024, on approximately normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.
    2 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Very Strong Up Up Up
    Historical KOD trend table...
    Date Alert Name Type % Chg
    Golden Cross Bullish 0.00%
    Wide Bands Range Expansion 0.00%
    Overbought Stochastic Strength 0.00%
    Up 3 Days in a Row Strength 0.00%
    Spinning Top Other 4.92%
    Calm After Storm Range Contraction 4.92%
    Wide Bands Range Expansion 4.92%
    Overbought Stochastic Strength 4.92%
    Calm After Storm Range Contraction 6.91%
    Wide Bands Range Expansion 6.91%
    Older End-of-Day Signals for KOD ...

       Recent Intraday Alerts

    Alert Time
    60 Minute Opening Range Breakout 1 day ago
    Up 5% 1 day ago
    Up 1 ATR 1 day ago
    Rose Above Previous Day's High 1 day ago
    Up 3% 1 day ago
    View Earlier Intraday Alerts

    Free Daily (Stock) Chart Reading

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Analyze My Stocks!
    Configure default chart indicators
    KOD Chart by TradingView
    Basic chart:

    Profile

    Kodiak Sciences Inc Description

    Kodiak Sciences Inc., a clinical stage biopharmaceutical company, provides novel therapeutics to treat retinal diseases. The company's lead product candidate is KSI-301, a vascular endothelial growth factor (VEGF)-biological agent that is in Phase 1b clinical study to treat wet age-related macular degeneration (AMD) and diabetic retinopathy. Its preclinical stage product candidate include KSI-501, a bispecific anti-interleukin 6/VEGF bioconjugate to target inflammation and abnormal angiogenesis in the pathogenesis of retinal vascular diseases. The company's early research pipeline include KSI-601, a triplet inhibitor for dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was founded in 2009 and is headquartered in Palo Alto, California.

    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Organ Systems Inflammation Ophthalmology Macular Degeneration Vascular Disease Diabetic Retinopathy Retina Wet Age Related Macular Degeneration Preclinical Stage Product Retinopathy Angiology Retinal Diseases Angiogenesis Retinal Disease Vascular Endothelial Growth Factor

    Is KOD a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Nov 15 Kodiak: Tarcocimab Faces High Barriers To Entry Despite Resurrection (Rating Upgrade)
    Nov 15 Kodiak Q3 Loss Narrower Than Expected, Pipeline Development in Focus
    Nov 14 Kodiak Sciences GAAP EPS of -$0.84 beats by $0.07
    Nov 14 Kodiak Sciences Announces Recent Business Highlights and Third Quarter 2024 Financial Results
    Nov 11 Kodiak Sciences to Participate in Upcoming Investor Conferences
    Oct 21 3 US Penny Stocks With Market Caps Under $500M To Consider
    Oct 14 Kodiak Sciences to Present at Innovate Retina 2024
    Oct 10 Kodiak Counts on Tarcocimab Eye Disease Program Despite Setbacks
    Sep 23 Kodiak Sciences to Host Investor R&D Day Today at 10:30am Eastern Time
    Sep 18 We Think Kodiak Sciences (NASDAQ:KOD) Needs To Drive Business Growth Carefully
    See more KOD news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 7.77
    52 Week Low 2.185
    Average Volume 295,052
    200-Day Moving Average 3.68
    50-Day Moving Average 3.69
    20-Day Moving Average 4.90
    10-Day Moving Average 5.59
    Average True Range 0.35
    RSI (14) 82.55
    ADX 68.02
    +DI 38.88
    -DI 2.05
    Chandelier Exit (Long, 3 ATRs) 5.23
    Chandelier Exit (Short, 3 ATRs) 4.45
    Upper Bollinger Bands 6.48
    Lower Bollinger Band 3.31
    Percent B (%b) 0.91
    BandWidth 64.75
    MACD Line 0.68
    MACD Signal Line 0.61
    MACD Histogram 0.0695
    Fundamentals Value
    Market Cap 324.8 Million
    Num Shares 52.5 Million
    EPS -5.19
    Price-to-Earnings (P/E) Ratio -1.19
    Price-to-Sales 0.00
    Price-to-Book 0.93
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 6.93
    Resistance 3 (R3) 6.87 6.58 6.80
    Resistance 2 (R2) 6.58 6.39 6.60 6.76
    Resistance 1 (R1) 6.38 6.27 6.48 6.44 6.72
    Pivot Point 6.09 6.09 6.14 6.11 6.09
    Support 1 (S1) 5.89 5.90 5.99 5.95 5.66
    Support 2 (S2) 5.60 5.78 5.62 5.62
    Support 3 (S3) 5.40 5.60 5.58
    Support 4 (S4) 5.46